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Murine placentation is associated with the invasion of maternal endometrium by trophoblasts and 
an extensive maternal and foetal angiogenesis. Plasminogen activator inhibitor-1 (PAI-1) is 
transiently produced by spongiotrophoblasts and trophoblast giant cells at 10.5-11.5 day post-
coitum (dpc). Knowing the key contribution of PAI-1 in the regulation of angiogenesis, we have 
now analyzed the consequence of PAI-1 deficiency on murine placentation. Morphological and 
quantitative computer-assisted image analysis revealed abnormal placental morphology in PAI-1 
-/-
 mice at 10.5 and 12.5 dpc. At 10.5 dpc, the genetic ablation of PAI-1 resulted in a transient 
reduction of both maternal and foetal vascularizations in the placenta and increased trophoblast 
cell density. This was associated with a poorer development of the labyrinth and an extension of 
the decidua. A larger spongiotrophoblast layer appeared at 12.5 dpc in PAI-1 deficient mice. 
Placental morphology was normalized at 14,5 dpc. Microarray analyses performed on laser 
capture microdissected labyrinths revealed that 46 genes were differentially expressed at 10.5 dpc 
between the two genotypes. However, only 11 genes were still differently modulated at 14.5 dpc 
when normalization of placental morphology had take place. This transcriptomic profiling 
highlighted a dysregulation in the expression of placenta-related cathepsin family members. All 
together our data provide evidence for a transient impaired placental morphology in PAI-1-
deficient mice which is then normalized leading to normal embryonic development.  
 





Extensive maternal and foetal vascular remodellings during placentation result in a large 
network of closely apposed but separated maternal and foetal circulations (24). The maternal 
uterine vascular bed changes dramatically during pregnancy as existing vessels dilate and new 
vessels form (13). In addition, in primates and rodents, terminal vascular bed is not lined by 
endothelial cells but is rather hemochorial, meaning that maternal blood perfuses a space lined 
by trophoblast cells. Failure in placental angiogenesis can lead to pregnancy disorders, including 
miscarriages, foetal growth restriction and preeclampsia (8). 
The precise molecular mechanisms that regulate maternal vascular development during 
gestation and its relationship to foetoplacental development are largely unknown. Adequate 
placentation involves successful invasion of uterine decidua by primary and secondary 
trophoblast cells. These cells express several factors with potent angiogenic (e.g., VEGF, 
Proliferin) and vasoactive (e.g., nitric oxide, Adrenomedullin) effects (13). Their invasive 
property is associated with their capacity to secrete serine proteases (plasminogen/plasmin), 
matrix metalloproteinases (MMPs) and cathepsins that degrade the extracellular matrix (37; 45). 
A functional synergism of both serine proteases and MMPs regulates vascularisation during 
placental development (48).  
The plasminogen/plasmin system consists of an inactive proenzyme, plasminogen which 
is converted into plasmin by urokinase-type plasminogen activator (uPA) or tissue-type 
plasminogen activator (tPA). Plasminogen activator inhibitor-1 (PAI-1) is a primary uPA 
regulator which inhibits uPA by forming a covalent complex, thus controlling the 
thrombotic/fibrinolytic process(7; 39). In addition, through its binding to the extracellular matrix 
(ECM), PAI-1 regulates cell adhesion and migration by interfering with the binding between 




The key role of PAI-1 in angiogenesis associated to cancer progression is well 
documented. In vivo experiments revealed that: (1) pharmacological PAI-1 levels prevent 
angiogenesis and tumorigenesis; (2) physiological PAI-1 levels inversely facilitate tumour 
growth and angiogenesis, and (3) tumour growth and angiogenesis are impaired in the absence of 
PAI-1 in mice (3; 20; 36). We have shown in several in vivo and in vitro models of angiogenesis 
that such angiogenic property of PAI-1 results from its ability to inhibit plasmin and thereby to 
protect endothelial cells from excessive proteolytic degradation (2-4; 20; 33; 39) and/or 
apoptosis (5). Based on the similarities between tumor cell invasion and trophoblast invasion 
(49), we extended our study by investigating the putative function of PAI-1 during physiological 
placentation through a genetic approach. Intriguing findings are the observations that PAI-1 
knockout mice are fertile and that their litter sizes are normal (11). During implantation, PAI-1 is 
produced specifically by spongiotrophoblasts and trophoblast giant cells at days 10.5-11.5 dpc 
(50). The cell specific and timely regulated expression of PAI-1 in placenta, suggest that it might 
play a significant role, during early phases of placental vascular remodelling. In the present 
study, we explored the putative role of PAI-1 during mouse placentation by analysing the 
vasculature and morphology of placenta at 10.5, 12.5 and 14.5 dpc in PAI-1 mice deficient or in 
their control counterparts. In order to evaluate gene expression modulation associated to PAI-1 
deficiency, laser capture microdissection (LCM) of labyrinth from PAI-1+/+ and PAI-1-/- mice 
followed by microarray analysis were carried out. We provide evidence for a transient 
perturbation of placental morphology associated with a deregulation at the transcript levels of 






2. MATERIALS AND METHODS 
 
2.1 Transgenic mice 
Homozygous mice with a single gene deficiency (PAI-1-/-) and the corresponding wild 
type animals (PAI-1+/+) were previously described (11). To generate homozygous embryos in 
mothers of the same genotype, homozygote knockout and WT females with proven fertility were 
mated with homozygotes knockout and WT males, respectively. Pregnancy was checked by 
occurrence of vaginal plugs in the morning. The day of vaginal copulation plug detection was 
designated as day 0.5 post-coitum (dpc). Embryos were collected at 10.5, 12.5 and 14.5 dpc. At 
each time point, 6 to 9 embryos were obtained from three different females. 
 
2.2 Tissue preparation 
At sacrifice, the two uterine horns were removed to isolate and separate the different feto-
placental units. Length and width of each of them were measured just after dissection. The feto-
placental units of first horn were fixed in 10% formaldehyde for 1 hour, at room temperature. 
Dehydration was achieved by incubating embryos, 2 times for 1 hour in increasing concentrations 
of alcohol (70% to 95% ethanol) followed by isopropanol and xylol. Specimens were then 
embedded in Paraplast Plus (Labonord, Rekkem, Belgium). The feto-placental units of second 
horn were embedded in Tissu-Teck (Labonord), snap frozen in liquid nitrogen, and stored at -
80oC until use. 
2.3 Histological analysis  
Serial sections (5 µm thick) were stained with Hematoxylin and Eosine or May-Grünwal-
Giemsa (MGG) staining (Merck, Darmstadt, Germany) for classical morphology analysis. To 




min, fixed with paraformaldehyde (PFA) 4% for 10 min, permeabilised in Triton X-100 1% for 5 
min, incubated with 1.5% milk and 0.5% Tween-20 for 30 min at room temperature and then 
incubated with primary antibody (Ab). Sections were then incubated, during 2h at room tempture, 
with anti-keratin Ab (rabbit anti-mouse, Z0622, DAKO, Denmark) diluted 1/200 (1). Sections 
were washed in PBS (5x 5min) before incubation with the appropriate secondary Ab (swine anti-
rabbit, DAKO) conjugated to tetramethyl-rhodamine isothiocyanate (TRITC) diluted 1/40, for 30 
min, at room temperature. 
Decidual cells were labeled by specific staining for desmin (9; 26) as follows: paraffin 
sections were heated (1.4 bar and 126oC for 11 min in 10 mM citrate buffer, pH 6). Incubation 
with monoclonal mouse anti-desmin Ab (M0760, DAKO) (diluted 1/100) was conducted for 30 
min at room temperature and detected with ARK system (K3954, DAKO) (9; 26). The DAB 
system was used for final staining.  
Panendothelial cell “MECA32” Ab (75861E, Pharmingen, San Jose, CA, USA ) was used 
to identify both maternal and foetal blood vessels (6). For this purpose, sections were fixed in 
acetone at -20oC for 10 min then in 80% methanol for 10 min at 4°C. The primary Ab (rat-anti 
mouse MECA32) diluted 1/10, was incubated overnight at 4oC followed by the appropriate 
secondary Ab for 30 min at room temperature then revealed with DAB system.  
Cell proliferation in mice placenta was performed by Ki-67 immunostaining as follow: 
paraffin sections were heated (1.4 bar and 126oC for 11 min in 10 mM target retrieval solution). 
Endogenous peroxydases were inactivated in 3% H2O2 solution for 20 min at RT followed by 
incubation with the universal blocking reagent (HK085-5KE, BioGenex, CA, USA). Ki-67 Ab 
(M7249, DAK0) (diluted 1/50) was applied for 60 min at RT. A biotinylated rabbit anti-rat 
(E468, DAKO) (diluted 1/300) was used as secondary Ab. Immunostaining was achieved by 30 




For each specific immunohistochemistry controls were performed by omitting the primary 
antibody (Desmine IHC) or by incubating the sections with nonspecific IgG at the same 
concentration as the primary antibody. Rabbit (X0936, DAKO) and rat (012-000-002, Jackson 
Immunoresearch, UK) immunoglobulin’s fractions were used for anti-keratin, anti-Ki67 and anti-
MECA32 IHC.  
 
 
2.4 May-Grünwald-Giemsa (MGG) staining 
Paraffin sections were incubated 20 min at 37°C with the May-Grünwald solution diluted 
1/8 with Sorensen buffer (pH 6.4) (Merck). After rinsing in Sorensen buffer, sections were 
stained 40 min with Giemsa solution (Merck) at 37°C (stock solution was diluted 1/75 with 
Sorensen buffer) and then incubated 4 min in 0,1% acetic acid (31). 
2.5 Quantification of trophoblast, foetal and maternal blood vessel density 
Image processing was performed by using Aphelion3.2 (Adsis, Meythet, France) 
software. Images were registered in the RGB color space, in which maternal erythrocytes 
appeared red whereas foetal red cells were colored as mauve dots and trophoblast cells as purple-
blue regions (Fig. 1a). Area of region of interest was manually delineated by drawing (Fig. 1b). 
Two windows were drawn manually in order to discriminate between maternal (Fig. 1c) and 
foetal vessels (Fig. 1d). The region corresponding to trophoblast cells (Fig. 1e) was then obtained 
by subtracting the images (c) and (d) from the image (b). Resulting images were binarized (Figs. 
1f, g, h) and maternal and foetal vessel and trophoblast cell densities were determined as the 
quotient between the surface occupied by maternal vessels, foetal vessels and trophoblast cells 





2.6 Morphometric analysis of labyrinth and decidua thickness 
Different zones including the labyrinth, the spongiotrophoblast, trophoblast giant cells 
and maternal decidua, were identified in hematoxylin-eosine stained sections. The widths of 
labyrinth, spongiotrophoblast and decidua were determined by drawing a line parallele to the 
basis of the labyrinth, identifying the midpoint of this line, and then extending a perpendicular 
line first to the outer edge of the spongiotrophoblast (junctional zone) and then up to the 
peripheral edge of the decidua (Fig. 2 G). These measures were used to determine the ratios 
between decidua/labyrinth and spongiotrophoblast/labyrinth.  
For these measurements, microscopic images of feto-placental sections stained with hematoxylin-
eosine were acquired via a numerical camera (Nikon, Coolpix 990, Tokyo, Japan) with identical 
magnification. For each sample, whole implantation site with the embryo in situ was cut and 
morphometric measurement was performed on 5 sections chosen in the extremities and the 
middle part of the placenta using the IMAGE J software. The average of these five values was 
determined for each implantation site. 
 
2.7 Laser Pressure Microdissection (LCM) and RNA extraction 
In order to isolate the labyrinth layer, 10 µm of foeto-placental frozen sections were carried 
out and labyrinth was microdissected. With this aim, 3 foeto-placental units from 3 different mice 
were used for each condition [(1) PAI-1+/+ at 10.5 dpc, (2) PAI-1-/- at 10.5 dpc, (3) PAI-1+/+ at 
14.5 dpc and (4) PAI-1-/- at 14.5 dpc]. The laser pressure catapulting technique was adapted from 
our previous study (42). Briefly, 8 to 10 serial frozen sections of each placenta were mounted 
onto PALM® Membrane Slides (0.17mm PEN) ready to use (PALM, Germany) and stored on ice 
until microdissection. The Robot-Microbeam (PALM) focused the laser (60nm) on the specimen 




microfuge cap. Samples were covered with 100 µl of TRIzol (Invitrogen, CA, USA) and stored at 
-80°C. For RNA extraction, 100 µl of TRIzol and 40 µl of chloroform were added to samples, 
mixed and centrifuged for 15 min at full speed at 4°C. Supernatant was measured and transferred 
in a new tube and then a same volume of 70% ethanol was added. Samples were mixed by 
pipetting. Purification of total RNA was performed with RNeasy Mini Kit (Qiagen, Venlo, 
Netherlands) according to manufacturer’s protocol.  
 
2.8 Transcriptome analysis 
For microarray study, RNA pools were used and contained equal amount of RNA from the 
labyrinth layer of 3 mice per conditions [(1) PAI-1+/+ at 10.5 dpc, (2) PAI-1-/- at 10.5 dpc, (3) 
PAI-1+/+ at 14.5 dpc and (4) PAI-1-/- at 14.5 dpc]. The RNA quality was assessed by automated 
elecrophoresis Experion System using the RNA StdSens Analysis kit (Bio-Rad). Four 
micrograms of total RNA were labeled using the GeneChip® Expression 3’ Amplification One-
Cycle Target Labeling kit (Affymetrix, Santa Clara, CA) following the manufacturer’s protocol. 
The cRNA was hybridized to Genechip Mouse Genome 430 2.0 (Affymetrix) according to the 
manifacturer’s protocol. Briefly, double-stranded cDNA was synthesized from 4 µg of total RNA 
primed with a poly-(dT)-T7 oligonucteotide. The cDNA was used in an in vitro transcription 
reaction (IVT) in the presence of T7 RNA polymerase and biotin-labeled modified nucleotides 
during 16 hours at 37°C. Biotinylated cRNA was purified and then fragmented (35-200 
nucleotides) together with hybridization controls and hybridized to the microarrays for 16 hours 
at 45°C. Using Fluidics Station (Affymetrix), the hybridized biotin-labeled cRNA was revealed 
by successive reactions with streptavidin R-phycoerythrin conjugate, biotinylated anti-
strepatvidine antibody and streptavidine R-phycoerythrin conjugate. The arrays were finally 




were imported in R software (http://www.r-project.org/) for data analysis. Data obtained after 
Affymetrix microarray hybridization analysis were normalized with the gcrma algorithm (29), 
available in the Bioconductor package (23). Differential analysis was performed with the varmixt 
package of R. A double-sided, unpaired t-test was computed for each gene between the two 
conditions. Variance of the difference in gene expression was split between subgroups of genes 
with homogeneous variance (17). 
 
2.9 cDNA synthesis and RT-PCR  
 
For cDNA synthesis, 1µg of total RNA was reverse transcribed with a Super Script First 
Strand Synthesis System (Invitrogen, Carslbad, USA) and random hexamers as primers. 
cathepsine 3 (Cts3), cathepsine M (CtsM), cathepsine 8 (Cts8), cathepsine E (CtsE), pregnancy-
specific-glycoprotein 19, 21 and 28 (Psg), prolactin-like protein F (PrlpF), trophoblast specific 
protein beta (Tpbpb) and fms-like tyrosine kinase 1 (Flt-1) RNA and 28S ribosomal RNA 
(rRNA) were measured in 10 ng aliquots of cDNA using Taq polymerase (Takara, Shiga, Japan) 
and 5 pmoles of specific primers (Eurogentec, Seraing, Belgium). Primers, amplification tempter 
and cycle’s number used for each gene are listed in Table 1. The thermal cycling included 2 min. 
at 95°C for denaturation and then amplification 15 sec. at 94°C, 20 sec at specific amplification 
tempeture (Table1) and then 20 sec. at 72°C with a final incubation 2 min. at 72°C. RT-PCR 
products were resolved on 10% polyacrylamide gels and analysed using a LAS-4000 Imaging 
(FujiFilm) after staining with Gelstar dye (FMC BioProduct, Rockland, ME, USA). mRNA 
products were quantified by normalization with respect to 28S rRNA. RT-PCR was performed in 
duplicate for each sample. 
 




For histological investigations, data were analyzed by using GraphPad 4.0 software (San 
Diego, CA). A Mann-Withney test was used to determine if difference between experimental 
groups could be considered as significant. For microarray, the raw P values were adjusted by the 
Bonferroni method, which controls the Family Wise Error Rate (FWER) (22). The level of 




3.1- Maternal and foetal vascularisations are reduced in PAI-1-/- mice at 10.5 dpc 
 
Since placental PAI-1 expression is restricted to days 10.5-11.5 dpc (50) we first 
examined PAI-1+/+ and PAI-1-/- implantation sites at 10.5 dpc when embryonic and maternal 
placental vessels invade the labyrinth. Placental circulation was assessed by the presence of 
vessels containing nucleated foetal erythrocytes stained in mauve by MGG (Fig. 2A). Remodeled 
maternal vessels where endothelial cells were substituted by trophoblast cells, were characterized 
by their content in red enucleated erythrocytes (Fig. 2A). Maternal and embryonic circulations 
were in close proximity in the labyrinth layer (Fig. 2A) which was composed of thin strands of 
trophoblast cells positive for keratin (Fig. 2C) intermingled with extensive networks of foetal and 
maternal vessels. In PAI-1-/- mice, the labyrinth was characterized by a dense network of thicker 
strands of keratin positive trophoblastic cells (Fig. 2D) which were poorly infiltrated by maternal 
and embryonic vessels (Fig. 2B).  
Both foetal and maternal blood vessel densities were significantly reduced in PAI-1 
deficient mice in comparison to WT mice (p< 0.02) (Figs. 3A, B). In addition, a 35% increase of 
trophoblast cell density was noted in PAI-1-/- mice (p= 0.0047) (Fig. 3C). Immunostaining of 




blood vessel number and confirmed the reduced development of the labyrinth in PAI-1-/- mice 
(Fig. 2E, F). No difference was seen in spongiotrophoblast layer between these two groups of 
mice. 
3.2- The labyrinth is poorly developed and the decidual layer is extended in PAI-1-/- mice at 
10.5 dpc  
The decidua identified with an anti-desmin antibody appeared larger in PAI-1-/- mice than 
in WT animals (Figs. 2G, H). A quantitative morphometric assessment of relative labyrinth and 
decidua thickness confirmed the relative poorer development of the labyrinth and the higher 
extension of the decidual layer in PAI-1-/- mice. The decidua/labyrinth ratio was 2.3-fold higher 
in PAI-1-/- than in their WT counterpart (Fig. 3D). This increased ratio was related to a thicker 
decidua and a thinner labyrinth layer in PAI-1-/- mice (p=0.0002). This is presumably the 
consequence of a decreased decidual invasion by trophoblast cells. 
Ki-67 immunohistochemistry, revealed that PAI-1-/- placentas presented a larger area or 
patches of Ki67 positive cells at the labyrinth layer comparing to PAI-1+/+ placentas (Fig.2I, J). 
This finding confirms that reduction of labyrinth layer in the absence of PAI-1 is correlated to 
differentiation delay of trophoblast cells.  
 
3.3- The labyrinthic vascularization is restored with a larger spongiotrophoblast layer in 
PAI-1-/- mice at 12.5dpc  
At day 12.5, when placental PAI-1 is no longer expressed, important differences appeared 
in the spongiotrophoblast (Fig. 4A, B). In PAI-1-/- mice, spongiotrophoblast appeared much 
denser with more trophoblast cells and less lacunar structures, leading to an increased thickness 
(Fig. 4B). Morphometric measurement revealed a 34% increased spongiotrophoblast/labyrinth 




PAI-1-/- mice (Fig. 5B). Thus, at day 12.5, PAI-1 deficiency led to a reduction of the labyrinth 
thickness and an enhancement of the thickness of spongiotrophoblast layer. However, in sharp 
contrast to the observation performed at 10.5 dpc, the labyrinth morphology (Figs. 4C, D) and 
vessel density (Figs. 4 E, F) evaluated with an anti-MECA32 antibody appeared identical in PAI-
1+/+ and PAI-1-/- mice, suggesting a normalization of the labyrinth structure. Quantification of 
foetal and maternal blood vessel and trophoblast cell densities confirmed these observations. 
 
3.4- Placental morphology is normalized in PAI-1-/- mice at 14.5 dpc 
At day 14.5, the placental morphology of PAI-1-/- and PAI-1+/+ mice were 
indistinguishable. The morphological differences observed in the placenta of PAI-1-/- or PAI-1+/+ 
mice, at days 10.5 and 12.5, were no longer present. The decidua/labyrinth ratio was identical in 
PAI-1+/+ and PAI-1-/- mice. Morphometric quantifications confirmed the restoration of a normal 
placental morphology in PAI-1 deficient mice. This observation demonstrates that the lack of 
PAI-1 transiently affected placental morphology and vascularisation which is then followed by a 
normalization of placental structure between 12.5 and 14.5 dpc. 
 
3.5- Phenotype observed at 10.5 dpc in PAI-1-/- mice is associated with gene modulation 
To assess the molecular basis of the impaired angiogenesis observed in PAI-1deficient 
mice, we performed a transcriptomic profiling using the Affymetrix Mouse Genome 430 2.0 
chips (34,000 genes) in the labyrinth layer of PAI-1+/+ and PAI-1-/- at 10.5 and 14.5 dpc. This 
microarray analysis revealed that more genes were significantly modulated during the course of 
pregnancy by comparing 10.5 dpc to 14.5 dpc than when comparing the two genotypes at 
identical lengths of pregnancy. Indeed, the comparison of gene expression between 10.5 dpc and 





 mice. Among those genes, 159 were co-expressed in the two genotypes (Figure 6A). When 
comparing PAI-1 proficient and deficient mice at the early time point, i.e. at 10.5 dpc when 
specific alteration of the labyrinth layer was histologically observed, only 46 genes were 
differentially expressed between PAI-1+/+ and PAI-1-/- (Figure 6B). Later on, at 14.5 dpc, when 
placental morphology was normalized, only 8 of these 46 genes were still differently regulated 
between the two genotypes. In addition, two additional genes appeared differently expressed at 
this latter time point. Features of the identified gene profile in PAI-1-deficient mice at 10.5dpc 
are that (1) most are related to molecules specifically expressed in the murine placenta (Fig. 6), 
and (2) no extracellular matrix components, MMPs or serine proteases has been identified. 
To validate this transcriptional profiling, quantitative RT-PCR assays were performed on 
the same RNA pools those used for microarray analysis. Among the regulated genes, we 
validated the RNA expression of those that are potentially implicated in the impaired 
angiogenesis and abnormal morphology. Results in Fig. 7 are expressed as the mRNA ratio in 
PAI+/+ to PAI-1-/- at 10.5 and 14.5 dpc. This analysis confirmed the up-regulation of cathepsin 8 
(Cts8) and the down-regulation observed at 10.5 dpc in PAI-1-deficient mice for cathepsin 3 
(Cts3), cathepsin M (CtsM), pregnancy-specific-glycoprotein (Psg) 19, 21 and 28, prolactin-like 
protein F (PrlpF), trophoblast specific protein beta (Tpbpb), and fms-like tyrosine kinase 1 (Flt-
1). In sharp contrast, such a differential regulation between the two genotypes was not anymore 
detected at 14.5 dpc (mRNA ratio around 1) (Fig.7), further supporting the normalization of 










PAI-1 contribution in pathological processes associated to abnormal angiogenesis such as 
cancer and age-related macular degeneration is well documented (4; 25; 33), but its function 
during the remodeling of maternal tissues associated with human embryo implantation is not yet 
fully determined (21; 28; 45). In mice, PAI-1 is essentially produced by spongiotrophoblast and 
trophoblast giant cells at days 10.5-11.5 dpc (50). Through a genetic approach, we tested the 
hypothesis that PAI-1, which is a key regulator of pathological angiogenesis could contribute to 
the control of placental angiogenesis. We provide, for the first time, evidence that PAI-1 gene 
deletion transiently affects the process of placentation. 
The lack of PAI-1 resulted at day 10.5 dpc, when PAI-1 is normally expressed by the 
trophoblasts, in an enlarged decidua and a reduced labyrinth layer due to trophoblast cells 
differenciation delay as evidenced by Ki-67 immunostaining. Similar results were also described 
with cystein cathepsin proteases in trophoblast function (47). Moreover, both maternal and foetal 
vessel densities were decreased. Prolactin immunohistochemistry revealed no difference in 
trophoblast giant cells density between PAI-1+/+ and PAI-1-/- mice (data not shown). At later time 
point (14.5 dpc) a normalization of placental morphology was evident. Such a normalization 
detected at a time when PAI-1 is no longer expressed in normal mouse pregnancy indicates that 
placental remodeling and embryo growth become subsequently independent from PAI-1 status. 
These data emphasize the importance of PAI-1 specifically at early steps of angiogenesis onset. 
They are on line with previous studies related to cancer progression (36).  
PAI-1 is a multifunctional molecule known to control not only extracellular matrix 
proteolysis, but also cell matrix interaction through binding to vitronectin and cell surface 




vivo and in vitro models of angiogenesis that PAI-1 plays a critical angiogenic role mainly 
through its capacity to tightly control extracellular proteolysis (4). The necessity of a balance 
between plasminogen activators and PAI-1, at least in pathological angiogenesis, is supported by 
evidence of a dose-dependent effect of PAI-1 (2; 20; 32). One function of PAI-1 may consist in 
the protection of angiogenic vascular endothelial cells or other migrating cells by preventing 
excessive pericellular proteolysis and cellular damage as well as by preserving matrix integrity 
(4; 10; 39; 41). We also recently reported that PAI-1 displays a proangiogenic activity by 
protecting endothelial cells from Fas-ligand mediated apoptosis induced by plasmin (5). 
Although, PAI-1 action could rely on the control of plasmin-mediated proteolysis, the absence of 
a phenotype in plasminogen-deficient mice suggests that the action of PAI-1 could not be simply 
related to this mechanism. In an attempt to determine whether impaired vascularisation in the 
labyrinth layer could be related to excessive extracellular matrix protein deposit, 
immunostainings of fibrin(ogen), collagen III and collagen VI were performed. However, no 
difference between the two genotypes of mice was detected (data not shown). Moreover, in both 
physiological (the present work) and pathological angiogenesis process, the phenotype associated 
to PAI-1 deficiency (impaired angiogenesis) is more severe than that observed in plasminogen-
deficient mice. Indeed, the defect of tumor vascularisation observed in PAI-1-/- mice could not be 
fully phenocopied by plasminogen deficiency(3) . Therefore, one can suggest that PAI-1controls 
placenta formation by regulating adhesive, migratory, and growth properties of invasive cells (15; 
38; 41). 
Transient elevated PAI-1 expression could serve to temporally and spatially modulate 
plasmin initiated peritrophoblast proteolysis further facilitating epithelial invasive potential.    
Microarray analysis performed on microdissected labyrinth layers demonstrated that 46 genes 




dpc, when placental morphologies normalization takes place, only 10 genes were found 
differentially regulated between PAI-1-/- and PAI-1+/+. Among the 38 genes modulated between 
PAI-1+/+ and PAI-1-/-, at 10.5 dpc, 20 (52%) were placenta-specific genes or placenta-specific 
members of gene families. Placenta-specific genes include the pregnancy-specific-glycoproteins 
(Psg) (44), and carcinoembyonic antigen-related cell adhesion molecules (Ceacam) (44) which 
both belong to the immunoglobulin super family, trophoblast specific protein b (Tpbpb), 
prolactine like protein (Prlp) and decidual/trophoblast prolactin-related protein (Dtrp) (30; 40). 
These gene modulations might reflect the morphological changes observed at early stage of 
placental formation. Surprisingly, the transcriptomic analysis did not reveal any modulation of 
serine proteases or MMPs, or their inhibitors. These two proteolytic systems have however been 
shown to display overlapping functions during embryo implantation and development (12; 14; 
45), as well as during physiological remodeling processes such as wound healing (34). In 
contrast, our study pinpointed a dysregulation in cystein cathepsin expression. Two murine 
cathepsins (cts3 and M) specifically expressed by spongiotrophoblasts were downregulated at 
10.5 dpc (37). In the opposite, cts8 transcripts mainly produced by giant trophoblastic cells were 
upregulated at this time point. In addition, the expression of Tpbps encoding a truncated protein 
with homology to cathepsin (19; 37) was repressed. Tpbps may function as inhibitors of 
cathepsin proteases. Little is known about the functions and targets of these cathepsins. Whether 
the transcriptomic modulation of murine cathepsin family members contribute to impaired 
angiogenesis or participate to the subsequent normalization of placenta development remains to 
be determined. In this context, it is intriguing to note that Cts8 whose transcripts were up-
regulated in PAI-1-deficient mice is produced by trophoblast cells that invade the maternal 
decidua and contribute to spiral artery remodeling (47; 52). Cts8 has been reported to endow 




Several compensatory angiogenic factors allowing mice to escape to the phenotype could 
be associated with PAI-1 deficiency. Indeed, we have previously shown that the angiogenic 
factor, FGF-1, is important for primary tumor growth and compensates the absence of PAI-1 
(35). However, no modulation of FGF-1 mRNA expression was observed in our microdissected 
samples (data not shown). In addition, angiogenic factors such as VEGF or Placental Like 
Growth Factor (PlGF) were not listed in our microarray analysis to be differentially regulated 
between PAI-1+/+ and PAI-1-/- mice. The unique known angiogenic factor to be modulated at 10.5 
dpc was fms-like tyrosine kinase 1 (Flt-1) (27). However, its down-regulation observed in PAI-1-
deficient mice likely reinforces the impaired placental vascularization rather than compensates 
for the lack of PAI-1.  
Altogether, our data show that, despite the unaffected pregnancy outcomes, transient 
morphological abnormalities at the level of labyrinth, spongiotrophoblast and decidua as well as 
modulation of several gene expressions by trophoblast cells, result from the deficiency of PAI-1 
at 10.5 and 12.5 dpc. Through a genetic approach, we provide new insights into the unique 
function of PAI-1, in the setup of placental maternal and foetal vascularisation.  
Successful human embryo implantation and placentation also requires a tight control of 
placental expression of proteases and of their inhibitors (53). Abnormalities in PAI-1 expression 
are documented in patient with reported implantation failures, early preeclampsia, HELLP 
syndrome (46; 51; 54). It is therefore interesting to speculate that the major transient placental 
abnormalities elicited by lack of PAI-1 expression in this murine model my also translate in 
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28S rRNA-FP 
28S rRNA-RP U13369 
5’-GTTCACCCACTAATAGGGAACGTGA-3’ 
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Figure 1:  
Quantification method of maternal vessels, foetal vessels and trophoblast cells by computer-
assisted image analysis. (a) Histological cross-section of labyrinth, (b) Window with isolated 
labyrinth layer, (c) Windows allowing the identification of maternal vessels, (d) foetal vessels 




Labyrinth and decidua histology in implantation sites of PAI-1+/+ (left panels) and PAI-1-/- (right 
panels) mice at 10.5 dpc. A-B: May-Grümwal-Giemsa staining of labyrinth layer. Foe: Foetal 
blood vessels; Ma: Maternal blood vessels; Tro: Trophoblast cells. C-D: Trophoblast cells 
staining using anti-keratin Ab. E-F: Labeling of foetal blood vessels using MECA-32 Ab in the 
labyrinth layer. G-H: Labeling of the decidua using anti-desmin Ab. I-J: labeling of cells 
proliferation using Ki-67 Ab. De: Decidua; Lab: Labyrinth; Sp: Spongiotrophoblast. 
 
Figure 3: 
A, B and C: Quantification of foetal and maternal blood vessels and trophoblast cell density at 
10.5 dpc, in PAI-1+/+ and PAI-1-/- mice. Quantification was performed according to the 
computer-assisted method described in materials and methods and in Fig 1. A: Foetal blood 
vessel density. B: Maternal blood vessel density. C: Trophoblast cells density. D: Decidua/ 
labyrinth ratio was determined by measuring the thickness of the decidua and the labyrinth on 




measurements were performed for each sample and results represent the average of all values. 
The number of implantation sites analyzed is indicated in each graph (n). 
 
Figure 4: 
Labyrinth, spongiotrophoblast and decidua histology and blood vessel architecture in 
implantation sites of PAI-1+/+ (left panels) and PAI-1-/- (right panels) at 12.5 dpc. A-B: Overview 
of the labyrinth layer with hematoxylin&eosin staining. C-D: Fluorescent labeling of trophoblast 
cells using anti-keratin Abs. E-F: Labeling of foetal blood vessels in the labyrinth layer using 
MECA-32 Abs. 
De: Decidua; Lab: Labyrinth; Sp: Spongiotrophoblast. 
 
Figure 5: 
Calculation of the Spongiotrophoblast/labyrinth (A) and decidua/ labyrinth (B) ratios at 12.5 dpc 
in PAI-1+/+ and PAI-1-/- mice. Decidua, spongiotrophoblast and labyrinth thickness were 
measured on microscopic images of hematoxylin-eosine stained sections of feto-placental unity 
as described in materials and methods. Five different measurements were performed for each 
sample and results represent the average of all values. The number of implantation sites analyzed 
is indicated (n). 
 
Figure 6: Venn diagram illustration of genes differentially modulated between PAI-1+/+ and PAI-
1-/- at 10.5 and 14.5 dpc by. The 38 genes modulated at 10.5 dpc are listed according to their 






Figure 7:  
 
Semi-quantitative RT-PCR analysis with the same RNA samples used in the transcriptomic 
analysis. Results are expressed as the mRNA ratio in PAI-1+/+ to PAI-1-/- at 10.5 and 14.5 dpc. 
PAI-1+/+/PAI-1-/- ratio of Psg19 (A), Psg21 (B), Psg28 (C), Prlpf (D), Tpbpb (E), Cts3 (F), CtsM 
(G), Cts E (H) Cts 8 (I) and Flt1 (J). Line indicate the value 1 of PAI-1+/+/PAI-1-/- ratio.  
 
 
 
 
 
 
